Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "2025"

1027 News Found

AstraZeneca delivers double-digit growth
News | November 10, 2025

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy


Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
News | November 10, 2025

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Marksans Pharma's Goa unit clears FDA inspection
News | November 10, 2025

Marksans Pharma's Goa unit clears FDA inspection

The said inspection concluded with Zero Form 483 observation


Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
News | November 09, 2025

Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr

Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025


Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
News | November 09, 2025

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025


Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
News | November 09, 2025

Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr

Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025


Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
News | November 09, 2025

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025


Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
News | November 09, 2025

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025


SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
News | November 09, 2025

SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr

SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025